Successful treatment of central nervous system involved Erdheim-Chester disease by intermediate-dose cytarabine as first-line therapy

Acta Oncol. 2020 Mar;59(3):302-305. doi: 10.1080/0284186X.2019.1670355. Epub 2019 Sep 27.

Authors

Ji-Nuo Wang¹, Yu Qiu¹, Na Niu², Yan Zhang¹, Jian Li¹, Dao-Bin Zhou¹, Xin-Xin Cao¹

Affiliations

¹ Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
² Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

PMID: 31559889
DOI: 10.1080/0284186X.2019.1670355

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Central Nervous System Diseases / complications
Central Nervous System Diseases / drug therapy*
Central Nervous System Diseases / pathology
Cytarabine / therapeutic use*
Erdheim-Chester Disease / complications
Erdheim-Chester Disease / drug therapy*
Erdheim-Chester Disease / pathology
Female
Humans
Immunosuppressive Agents / therapeutic use*
Prognosis
Young Adult

Substances

Immunosuppressive Agents
Cytarabine